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Abstract Bortezomib is effective in the therapy of mul-
tiple myeloma (MM), but causes infections that are dif-
ferent from those associated with conventional
chemotherapy. It is important to identify the risk factors
that facilitate infections associated with bortezomib ther-
apy. In the present report, we sought to (1) define the
features of the infections associated with this therapy and
(2) identify the immune mechanisms responsible for the
observed susceptibility to these infections. We first retro-
spectively analyzed the clinical data of 143 patients who
had received bortezomib therapy for MM. We then pro-
spectively assessed the modulation of T lymphocyte status
during this therapy, and evaluated potential relationships
between infections and T lymphocyte changes. The infec-
tion rates peaked during the first cycle of bortezomib
therapy (47.6 %) in patients with MM (p \ 0.05 vs. sub-
sequent cycles). Bortezomib therapy was associated with
higher incidence rates of viral and fungal infections
(15.8 %, p \ 0.05 vs. conventional chemotherapy). In
addition, patients with the IgG immunophenotype showed
higher bacterial and viral infection rates (respectively,
p = 0.008 and 0.009). The T lymphocyte numbers signif-
icantly decreased after bortezomib therapy (p \ 0.05), and
the same was true for the Th1/Th2 ratio (p \ 0.01).
Patients with MM who have decreased lymphocyte counts,
while on bortezomib therapy are more likely to develop
bacterial or viral infections. In addition, an imbalance in T
lymphocyte subsets is also associated with bacterial or viral
infections in these patients.
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Introduction
Introduction of novel drugs and hematopoietic stem cell
transplantation increased the remission rates and prolonged
the survival of patients with multiple myeloma (MM)
[1, 2]. However, infections still remain one of the major
causes of death in these patients [3]. Studies suggest that it
is both the tumor and suppression of immune function by
chemotherapy drugs that increase the risk of infections in
patients with MM [4]. Clinically, these infections typically
feature atypical symptoms, rapid progression, and the
presence of multiple pathogens [3, 4]. Advanced age of
patients with MM and the frequently occurring multiple
organ dysfunction complicate antimicrobial therapy [5].
Therefore, early prevention and diagnosis of infections are
crucial for effective management of MM.
Bortezomib, a proteasome inhibitor, is currently the
first-line medication in the treatment of MM. The drug is
characterized by rapid action, high efficacy, and low bone
marrow toxicity [2]. Bortezomib does not affect the inci-
dence of infections [6]. However, when they occur, these
infections are different from those associated with con-
ventional chemotherapy. Specifically, these infections are
caused by the less commonly occurring pathogens, such as
herpes zoster, and neutropenia is not the only causal factor
predisposing to these infections [7]. It is, therefore,
important to identify other risk factors that facilitate
infections associated with bortezomib therapy. In the
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present report, we sought to address the following two
objectives: (1) to define the features of the infections
associated with this therapy and (2) to identify the immune
mechanisms responsible for the observed susceptibility to
these infections. To this end, we retrospectively assessed
clinical features of infections in 143 patients with MM who
underwent the therapy with bortezomib, and prospectively
examined in 30 patients the changes in T lymphocyte
subsets during this therapy.
Materials and Methods
Patients
The international diagnostic and staging criteria for MM [8,
9] were utilized in our study. The first objective of the
study was to retrospectively assess infections in 143
patients with MM who received bortezomib therapy in the
Department of Hematology, First Affiliated Hospital of
Sun Yat-sen University, from January 2006 to May 2012.
We collected information on conditions of these patients,
changes in blood cell counts, and other particularities of the
infections. These data were compared with those of 124
patients with MM who underwent conventional chemo-
therapy (i.e., without bortezomib) during the same period
of time. The data from both groups of patients are pre-
sented in the Table 1.
In the prospective part of the study, we assessed the T
lymphocyte status in 30 patients who were treated with
bortezomib and 12 patients treated conventionally. The
latter patients served as controls. Patients from both groups
were also part of the above patient cohort.
Treatment
Patients treated with bortezomib received VD regimen
(bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11; dexa-
methasone 20 mg/day from day 1 to day 4) and PAD
regimen (bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11;
liposomal doxorubicin 40 mg/m2 on day 4; dexamethasone
20 mg/day from day 1 to day 4). A total of 545 cycles of
bortezomib chemotherapy were administered to 143
patients with MM.
Conventional chemotherapy included VADM regimen
(vincristine 0.5 mg/day from day 1 to day 4; pirarubicin
8 mg/m2 from day 1 to day 4; dexamethasone 20 mg/day
from day 1 to day 4; melphalan 9 mg/m2 from day 1 to day
4), DVD regimen (vincristine 1.4 mg/m2 on day 1; lipo-
somal doxorubicin 40 mg/m2 from day 1 to day 4; dexa-
methasone 20 mg/day from day 1 to day 4), and VAD
regimen (vincristine 0.5 mg/day from day 1 to day 4; pi-
rarubicin 8 mg/m2 from day 1 to day 4; dexamethasone
20 mg/d from day 1 to day 4). A total of 460 cycles of
conventional chemotherapy were administered to 124
patients with MM.
The study was approved by the Human Ethics Com-
mittee of our Hospital, and informed consents were
obtained from all the subjects.
Definition and Classification of Infections
Infectious pathogens assessed in this study included bac-
teria, viruses, and fungi. We defined the time from the
onset of infection-related symptoms/signs and radio-
graphic/laboratory abnormalities until complete remission
of the symptoms with negative radiographic and laboratory
findings after specific treatment as one infection incident.
The number of infection incidents per treatment cycle was
calculated in each group.
The infections were classified based on their pathogenic
nature into bacterial, viral, and fungal infections. Bacterial
infections included those caused by Gram-positive bacte-
ria, such as Staphylococcus aureus and Streptococcus
pneumoniae, and those by Gram-negative bacteria, such as
Escherichia coli and Klebsiella pneumoniae [10]. Viral
infections included the ones caused by varicella-zoster
viruses, hepatitis B viruses, and herpes simplex viruses
[11–13]. Fungal infections included infections with
Aspergillus and Candida [14, 15].
T Lymphocyte Isolation and Culture
Six millilitre of fasting venous blood was collected from
the cubital vein in early mornings of each day before the
initial, second, third, and fifth cycles of chemotherapy. The
blood was anticoagulated with heparin and EDTA, and
used for complete blood cell count, analysis of T lym-
phocyte subsets, serum immunofixation electrophoresis,
urinary Bence Jones protein testing, serum immunoglobu-
lin analysis, and b2-microglobulin detection. Peripheral
blood mononuclear cells were isolated using the human








Gender (M/F) 96/47 59/65 0.001
Median age (years,
range)
56 (27–78) 62 (34–78) \0.001
D-S staging (2/3) 11/132 17/107 0.109
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lymphocyte separation medium (ICN Biomedical Inc.,
Aurora, USA), washed with PBS (HyClone Laboratories,
Logan, USA), and cultured in RPMI 1640 medium con-
taining 10 % fetal calf serum (Life Technologies; Cergy,
Pontoise, France).
Cell Stimulation
A 3 ml aliquot of blood mononuclear cells was added to a
culture dish and stimulated with 3 ll of 50 lg/l PMA, 3 ll
of 1 lmol/l ionomycin (both from Sigma-Aldrich; St.
Louis, USA), and 2 ll of 2 lmol/l monensin (BD Biosci-
ences; San Jose, USA). Subsequently, the cells were
incubated at 37 C for 5 h. After stimulation, the cells were
stained with antibodies for 30 min. The antibodies included
Multitest 6-color TBNK, Th cell detection kit, CD69 APC
(all from BD Biosciences), and Treg cell kit (eBioscience;
San Diego, USA). The cells were washed and resuspended
in PBS, and then analyzed by flow cytometry (BD
FASCanto system) for expressions of CD69. The expres-
sion level of higher than 90 % was defined as cell
activation.
Flow Cytometry of Peripheral Blood T Cell Subsets
Unstimulated samples were stained with CD45-PerCP-
Cy5.5, CD3-FITC, CD4-PE-Cy7, and CD8-APC-Cy7
monoclonal antibodies (all from BD Biosciences), and the
ratio of peripheral Th/CTL cells was quantified. Further,
unstimulated samples were stained with CD4-FITC and
CD25-APC (eBioscience). Then, the cells were permeabi-
lized using permeabilization buffer (eBioscience) and
subsequently stained intracellularly with FOXP3-PE
(eBioscience) to quantify the ratio of peripheral Treg cells.
Stimulated samples were stained using CD4-APC (BD
Biosciences). The cells were permeabilized using the BD
Cytofix/Cytoperm buffer (BD Bioscience) and subsequently
stained intracellularly with IFN-c-FITC, IL-4-PE, and
Th-17-PE antibodies to quantify the ratio of peripheral Th1,
Th2, and Th17 cells.
The cytometric data were analyzed using BD FASCanto
system (BD Biosciences). The analysis procedure was done
as shown in Figs. 1, 2, 3, and 4.
Statistical Analysis
The statistical analysis was performed with SPSS 17.0
(SPSS Inc.; Tokyo, Japan). Categorical variables were
analyzed using the Chi-square test, not normally distributed
quantitative variables using the Wilcoxon test, and nor-
mally distributed data by t test. A Spearman correlation
analysis was conducted to assess the correlation between
categorical variables. A p value of \0.05 was defined as
statistically significant.
Results
Infections in Patients Receiving Different
Chemotherapy Regimens
The overall infection rate was slightly higher in patients
who received bortezomib compared with those on con-
ventional chemotherapy (respectively, 34.9 vs. 30.7 %,
p = 0.079). Specifically, the overall infection rate was
significantly higher in the bortezomib group during the first
cycle of therapy (p \ 0.05 vs. the subsequent cycles;
Fig. 5), while there were no significant differences during
subsequent cycles (Fig. 5).
Further, the use of bortezomib was associated with
higher incidence rates of viral and fungal infections
(p \ 0.05 vs. conventional chemotherapy). Conversely, the
rates of bacterial infections were lower in the bortezomib
group (p = 0.038 vs. conventional chemotherapy; Fig. 6).
Fig. 1 Flow cytometry analysis of CD69 expression in stimulated lymphocytes. a Gate set on peripheral blood lymphocytes; b gate set on CD4?
T lymphocytes; and c gate set on CD69? T lymphocytes. Numbers represent respective percentages
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In addition, the first two cycles of bortezomib therapy were
associated with significantly higher incidence rates of
bacterial and viral infections, compared with the sub-
sequent cycles (respectively, 28.3 vs. 17.5 %, p = 0.032;
8.4 vs. 2.2 %, p = 0.002; Fig. 7).
Following bortezomib therapy, patients with the IgG
immunophenotype had a significantly higher infection rate
compared with those with non-IgG immunophenotypes
(42.2 vs. 28.6 %, p \ 0.001). Further analysis revealed that
this was due to higher bacterial and viral infection rates
Fig. 2 Flow cytometry analysis of lymphocyte subsets. a Gate set on CD45? CD3? T lymphocytes; b gate set on CD3? CD4? Th cells; and
c gate set on CD3? CD8? CTL cells. Numbers represent respective percentages
Fig. 3 Flow cytometry analysis of Treg cells. a Gate set on CD4? Th cells; b gate set on CD4? CD25? Th cells; and c gate set on CD4? CD25?
FOXP3? Treg cells. Numbers represent respective percentages
Fig. 4 Flow cytometry analysis of Th1, Th2, and Th17 cells. a Gate set on CD4? IFN-c? Th1 lymphocytes; b gate set on CD4? IL-4? Th2
lymphocytes; and c gate set on CD4? IL-17? Th17 lymphocytes. Numbers represent respective percentages
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(respectively, 23.4 vs. 15.1 %, p = 0.008; 7.3 vs. 2.9 %,
p = 0.009), while there was no difference in fungal
infection rate between those with or without IgG immun-
ophenotypes (11.5 vs. 10.4 %).
Relationship Between Lymphocyte Counts
and Infections
After the therapy with bortezomib, decreased lymphocyte
counts (\1.0 9 109/l) were observed in 23.6 % of patients
with MM. Also, these patients showed a higher infection
rate compared with patients with normal lymphocyte
counts (38.9 vs. 30.8 %, p = 0.007). Furthermore, patients
with decreased lymphocytes were more likely to have
higher infection rates if they were treated with bortezomib
(44.7 vs. 31.1 % in those with normal lymphocytes;
p = 0.002), whereas no such significant difference was
observed in patients who received conventional chemo-
therapy (32.6 vs. 30.4 %). A lymphocyte count of
\1.0 9 109/l weakly correlated with the occurrence of
infection following chemotherapy in the bortezomib group
(R = 0.127, p = 0.044).
In the bortezomib group, patients with decreased lym-
phocyte counts had a significantly higher rate of viral
infections compared with those with normal lymphocyte
counts (8.7 vs. 3.5 %, p = 0.007). However, this was not
true for bacterial and fungal infections. A lymphocyte
count of \1.0 9 109/l weakly correlated with the occur-
rence of viral infections following bortezomib therapy
(R = 0.105, p = 0.048).
Fig. 5 Infection rates during treatment cycles in patients receiving
bortezomib therapy or conventional chemotherapy. * p \ 0.05;
** p \ 0.01
Fig. 6 Infections with different pathogens in patients receiving
bortezomib therapy or conventional chemotherapy. * p \ 0.05;
** p \ 0.01
Fig. 7 Kinetics of rates of infection with different pathogens in the
bortezomib group
Fig. 8 Kinetics of changes in T lymphocytes in patients receiving
bortezomib therapy or conventional chemotherapy
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Effects of Bortezomib Regimen on T Lymphocytes
Bortezomib therapy decreased T lymphocyte counts fol-
lowing the first, second, and forth cycles (p \ 0.05 vs.
baseline levels; Fig. 8). By contrast, in the conventional
chemotherapy group, these decreased counts were only
observed during the first cycle (p = 0.039; Fig. 8).
A further analysis of T lymphocyte subsets showed
decreased counts of the Th, CTL, and Treg subsets in the
bortezomib group during the first, second, and forth
cycles,compared with the baseline (p \ 0.05; Fig. 9).
Based on the secreted cytokines and functions, Th cells
were divided into the Th1, Th2, and Th17 subsets. Fol-
lowing the dynamic monitoring and analysis, the lowest
Th1/Th2 ratio and Treg counts were observed after the first
cycle of bortezomib therapy (p \ 0.01), while the lowest
Th1/Th17 ratio was found after the forth cycle (p = 0.007;
Fig. 10).
In the bortezomib group, patients with bacterial infec-
tions had a significantly lower Th1/Th2 ratio (1.94 vs. 1.97,
p = 0.047 vs. patients without bacterial infections). In
addition, the Th1/Th2 ratio after therapy with bortezomib
moderately correlated with the occurrence of bacterial
infection (R = 0.574, p = 0.047). By contrast, patients
treated with conventional chemotherapy did not show the
association observed above (2.09 vs. 2.53 in patients with
and without bacterial infections; p = 0.473).
A lower Th1/Th2 ratio was also frequently found in
patients who received bortezomib and experienced viral
infections (1.56 vs. 1.93, p = 0.026 vs. patients without
viral infections) (Table 2). Similar to bacterial infections,
the Th1/Th2 ratio after bortezomib chemotherapy moder-
ately correlated with the incidence rates of viral infections
(R = 0.463, p = 0.042) (Table 2). Since no viral infec-
tions occurred in 12 patients on conventional chemother-
apy, no analysis of correlation between viral infections and
Th1/Th2 ratio was carried out (Table 2).
Discussion
The use of hematopoietic stem cell transplantation and new
pharmacological drugs, such as bortezomib, thalidomide and
lenalidomide, helped to achieve higher remission rates and to
prolong survival in patients with MM [2]. However, the rates
of infections associated with the therapy did not diminish,
although the pattern of these infections changed [4].
As observed in our study, patients receiving bortezomib
therapy experienced most infections following the first cycle
of chemotherapy, with a gradual decrease in the subsequent
cycles. Further, patients who received this therapy had
infections with different pathogens compared with patients
on conventional chemotherapy.
The unique clinical features associated with infections in
the bortezomib group may be caused by pharmacological
mechanisms of this agent. As a proteasome inhibitor,
bortezomib primarily blocks the NF-jB pathway, inhibit-
ing cell proliferation and differentiation. In addition to
Fig. 9 Changes in Th and CTL lymphocytes following the bortezo-
mib therapy. * p \ 0.05; ** p \ 0.01
Fig. 10 Changes in Th1/Th2 and Th1/Th17 ratios following the
bortezomib therapy. * p \ 0.05; ** p \ 0.01
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blocking the proliferation of tumor cells, it also inhibits
normal T cells, NK cells, DC cells, and other immune cells
[15–18]. Animal studies demonstrated that bortezomib can
diminish T cell responses against viruses, reduce Th1-type
immune responses, and promote viral proliferation [15–
18]. People with functional defects in T lymphocytes are
known to have higher incidences of viral and fungal
infections [19]. In this regard, our study also revealed
higher viral and fungal infection rates in patients with MM
on bortezomib therapy. Therefore, we hypothesized that
bortezomib-related clinical infections in these patients are
associated with declined immune function of the
lymphocytes.
Our studies confirmed the hypothesis. Specifically,
decrease in lymphocyte numbers correlated with the inci-
dence of post-therapy infections in the bortezomib group,
which was different from patients receiving conventional
chemotherapy. This was consistent with previously pub-
lished findings [6]. Also, it was observed by others [20] that
bortezomib inhibits T lymphocyte subsets in treated
patients and disturbs the balance among lymphocyte sub-
sets. Our analysis of the changes in lymphocyte subsets
after therapy with bortezomib showed an overlap between
the peak of inhibition of T cell subsets and peak occurrence
of infections. Subsequently, we demonstrated that the Th1/
Th2 ratio after bortezomib therapy correlated with the
incidence of viral infections.
Thereby, we demonstrate that infections occurring in
patients with MM during bortezomib therapy are associ-
ated with T lymphocyte functional defects. Therefore,
patients with lymphocytopenia and Th1/Th2 imbalance
after this therapy should be regarded as being at high risk
for infections and should be managed with strict infection
control measures. In these patients, preventive measures to
improve their neutrophil counts and humoral immune
functions are not sufficient. Since the infections following
bortezomib therapy are associated with T cell immune
dysfunctions, the use of immunomodulatory agents, such as
thymosin, to enhance the immune function of T lympho-
cytes may be useful in preventing infections in these
patients.
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